智通财经APP讯,诚达药业(301201.SZ)公告,公司收到国家药品监督管理局核准签发的达格列净原料药《化学原料药上市申请批准通知书》。相关药品适应症:在饮食和运动基础上,本品可作为单药治疗用于2型糖尿病成人患者改善血糖控制。本品不适用于治疗1型糖尿病或糖尿病酮症酸中毒。
智通财经APP讯,诚达药业(301201.SZ)公告,公司收到国家药品监督管理局核准签发的达格列净原料药《化学原料药上市申请批准通知书》。相关药品适应症:在饮食和运动基础上,本品可作为单药治疗用于2型糖尿病成人患者改善血糖控制。本品不适用于治疗1型糖尿病或糖尿病酮症酸中毒。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.